Medtronic plc (MDT) Earnings History

Medtronic plc - Q2 FY2026 Earnings

Filed at: Nov 18, 2025, 6:47 AM EST|Read from source

EXECUTIVE SUMMARY

Medtronic reported a strong second quarter of fiscal year 2026, exceeding expectations for both revenue and EPS, driven by robust procedure volumes and accelerating growth in key enterprise drivers.

POSITIVE HIGHLIGHTS

  • •

    Revenue of $9.0 billion increased 6.6% as reported and 5.5% organic, exceeding guidance.

    positive
  • •

    GAAP diluted EPS of $1.07 and non-GAAP diluted EPS of $1.36 both increased 8%, surpassing guidance.

    positive
  • •

    Cardiac Ablation Solutions revenue surged 71%, with U.S. growth at 128%, driven by the PFA portfolio.

    positive
  • •

    Cardiovascular portfolio showed its strongest growth in over a decade, excluding pandemic impacts.

    positive
  • •

    Raised FY26 guidance for organic revenue growth to approximately 5.5% and adjusted EPS to $5.62-$5.66.

    positive

CONCERNS & RISKS

  • •

    GAAP operating profit margin decreased by 20 basis points to 18.8%, and non-GAAP operating profit margin also decreased by 20 basis points to 24.1%.

    attention
  • •

    Medical Surgical Portfolio revenue growth was modest at 2.1% reported and 1.3% organic.

    attention
  • •

    Neuroscience Portfolio revenue growth was 4.5% reported and 3.9% organic, with Specialty Therapies showing a flat organic result.

    attention

FINANCIAL METRICS

Revenue
Quarterly
$8.96B
+6.6%
Prior year: $8.40B
Annual (YTD)
$17.54B
N/A
Prior year: $16.32B
Net Income
Quarterly
$1.37B
+8.2%
Prior year: $1.27B
Annual (YTD)
$2.41B
N/A
Prior year: $2.31B
EPS (Diluted)
Quarterly
$1.07
+8.1%
Prior year: $0.99
Annual (YTD)
$1.87
N/A
Prior year: $1.79
Operating Income
Quarterly
$1.69B
+5.7%
Prior year: $1.59B
Annual (YTD)
$3.13B
N/A
Prior year: $2.87B
EPS (Basic)
Quarterly
$1.07
+8.1%
Prior year: $0.99
Annual (YTD)
$1.88
N/A
Prior year: $1.79

MARGIN ANALYSIS

Gross Margin
Current Quarter
65.8%
Prior Year
64.9%
YoY Change
+90 bps
Operating Margin
Current Quarter
18.8%
Prior Year
19.0%
YoY Change
-20 bps
Net Margin
Current Quarter
15.3%
Prior Year
15.1%
YoY Change
+22 bps

Margin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.

REVENUE BY SEGMENT — Q2 FY2026 2026

VISUAL OVERVIEW

|
Cardiovascular Portfolio(3 segments)
38.5%
$3436000.0B
(+10.8% YoY)
Prior year: $3102000.0B
Neuroscience Portfolio(3 segments)
28.7%
$2562000.0B
(+4.5% YoY)
Prior year: $2451000.0B
Medical Surgical Portfolio(2 segments)
24.3%
$2171000.0B
(+2.1% YoY)
Prior year: $2128000.0B
Diabetes
8.5%
$757000.0B
(+10.3% YoY)
Prior year: $686000.0B

DETAILED BREAKDOWN

|
SegmentCurrentPrior YrYoY% Total
Cardiovascular Portfolio
$3436000.0B$3102000.0B+10.8%38.5%
Neuroscience Portfolio
$2562000.0B$2451000.0B+4.5%28.7%
Medical Surgical Portfolio
$2171000.0B$2128000.0B+2.1%24.3%
Diabetes
$757000.0B$686000.0B+10.3%8.5%
Total Revenue$8926000.0B——100.0%

Segment performance shows business unit health and growth drivers.

MANAGEMENT GUIDANCE

FY26

organic revenue growth
$5.5M—$5.5M
Mid-point: $5.5M
"Raised from prior guidance of approximately 5.0%."
adjusted EPS
$5.62—$5.66
Mid-point: $5.64
"Raised from prior guidance of $5.60 to $5.66. Includes a potential impact from tariffs of approximately $185 million, unchanged."

Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.

MANAGEMENT COMMENTARY

Delivered a strong second quarter with both revenue and EPS beating expectations.

— Medtronic plc, Q2 FY2026 2026 Earnings Call

Procedure volumes and end markets are robust, with good execution across the business.

— Medtronic plc, Q2 FY2026 2026 Earnings Call

Positioned for even greater acceleration of revenue growth in the back half of the year and beyond.

— Medtronic plc, Q2 FY2026 2026 Earnings Call

Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.

OPERATIONAL METRICS

Acute Care Monitoring Organic Growth
3
percent
Cardiac Ablation Solutions Us Growth
128
percent
Cardiac Rhythm Heart Failure Organic Growth
15.7
percent
Coronary Peripheral Vascular Organic Growth
1.9
percent
Cranial Spinal Technologies Organic Growth
5.2
percent
Diabetes Organic Growth
7.1
percent
Neuromodulation Organic Growth
8.3
percent
Specialty Therapies Organic Growth
0.9
percent
Structural Heart Aortic Organic Growth
8.5
percent
Surgical Endoscopy Organic Growth
1.8
percent

Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.